Lab technicians working

About Us

Meet the team ready to see human and scientific potential realized

Strong team of experts in virology, plant-expression and medicine

We’re a team of future-minded individuals working to make the world a healthier place.

Patrick Doyle

Patrick Doyle

Chief Executive Officer

Patrick Doyle has more than 20 years of leadership experience within pharmaceutical and biotech companies around the world. He is a proven leader with a track record of innovation, talent development, and a deep knowledge of pharmaceutical development, M&A and pathways to successful commercialization. He most recently served as CEO of Stelexis Therapeutics in New York, a biotech company with a proprietary platform to discover and selectively target pre-cancerous stem cells. Mr. Doyle has also been responsible for multiple financings and strategic exits of biotechs of various stages of development. During his Big Pharma tenure, he led an international group of corporate development executives executing several large alliances in Asia and Japan.

Patrick is originally from the UK, and has worked in the UK, Switzerland, California and more recently in New York City. He has a BSc in Pharmacology from the University of Sunderland.

Dr. Gregory Pogue headshot

Dr. Gregory Pogue

Scientific Consultant

Dr. Pogue is an expert in virology and molecular biology. He has held VP or above roles in six startups; one IPO’d on NASDAQ, a second acquired by a Fortune 500 company, and three obtained large licensing deals. He is a former FDA reviewer and has published more than 60 scientific articles and issued more than 35 patents.

Barry Bratcher headshot

Barry Bratcher

Chief Operating Officer

Barry was a co-founder of KBP and has been Director of Operations since its inception. He has over 30 years of experience developing and running cGMP processes for expressing and purifying recombinant proteins and plants. He oversaw the 2014-2016 execution of over 60 consecutive cGMP runs of the zMapp anti-Ebola monoclonal antibody.

Striving to be at the forefront of global health efforts

We have a vision to become a world leader in plant-based biologics. Discover our story and how we are working to pave the way for a better tomorrow using our plant-based platform and innovative technologies. BAT-owned KBP is located in Owensboro, Ky., where it began operations in 2006. In January 2014, KBP was acquired by and became an independently operated, wholly-owned subsidiary of Reynolds American Inc. (RAI), owned by BAT.

2014

Produced an anti-Ebola monoclonal antibody cocktail ZMappTM in partnership with MappBio. Went from project start to clinical drug substance in under 6 weeks.

2014

Promising pre-clinical evidence showing the potential for our vaccine platform in pandemic Flu (Mallajosyula, Jyothi K., et al. 2014).

2015

Produced a monoclonal antibody intended to block sexual transmission of genital herpes and HIV for Phase I trials in collaboration with MappBio (MB66).

2020

Entered Phase I clinical trials with our investigational Quadrivalent Flu vaccine candidate.

2020

Entered Phase I clinical trials with our investigational COVID vaccine candidate.